700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated